In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive
cellular therapy to treat cancer by modulating the immune response have led to …

Cancer is one of the most deadly diseases in the modern world. The last decade has
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …

Immune cell functions are regulated by co-inhibitory and co-stimulatory receptors. The first
two generations of cancer immunotherapy agents consist primarily of antagonist antibodies …

T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in
resected tumor samples derived from long-surviving patients, and impressive clinical …

Recent success in cancer immunotherapy has reinvigorated the hypothesis that the immune
system can control many if not most cancers, in some cases producing durable responses in …

Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming
toward a proinflammatory activation state represent different strategies to therapeutically …

Immune checkpoint inhibitor therapy has revolutionized the treatment of advanced
malignancies in recent years. Numerous reports have detailed the myriad of possible …

Purpose The cell-surface molecule CD40 activates antigen-presenting cells and enhances
immune responses. CD40 is also expressed by solid tumors, but its engagement results in …

A high activatory/inhibitory FcγR binding ratio is critical for the activity of mAb such as
rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting …

Abstract Cluster of differentiation 40 (CD40) mediates many immune activities. Preclinical
studies have shown that activation of CD40 can evoke massive antineoplastic effects in …